ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 125

Feasibility and Pilot Study of Mental Health Screening in Juvenile Myositis

Kaveh Ardalan1, Alison Manning 1, Brian Feldman 2, Gary Maslow 1 and Andrea Knight 3, 1Duke University Medical Center, Durham, 2The Hospital for Sick Children, Toronto, Canada, 3SickKids Research Institute, Toronto, Canada

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: health behaviors, juvenile dermatomyositis, juvenile myositis, mental health, outcomes

  • Tweet
  • Email
  • Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Saturday, May 2, 2020

Title: Poster Session 3

Session Type: ACR Abstract Session

Session Time: 4:15PM-5:15PM

Background/Purpose: Juvenile myositis (JM) negatively affects health-related quality of life due to chronic weakness, skin/muscle damage, multiorgan dysfunction, and side effects of immunosuppression. While JM’s impact on physical functional outcomes is well documented, there is a paucity of research assessing mental health comorbidities and their association with physical health outcomes in this high-risk population. This pilot study will assess feasibility of mental health screening in JM and test associations of mental health symptoms with disease outcome measures and healthy behaviors in JM.

Methods: Patients with JM aged 5-21 years old and their parents will be eligible for enrollment at Duke University Medical Center (Durham, NC) and Hospital for Sick Children (Toronto, ON). Self-report mental health screening for patients 12+ years old will be conducted using Pediatric Symptom Checklist-17 (PSC-17), Patient Health Questionnaire-9 (PHQ-9), and Generalized Anxiety Disorder-7 (GAD-7); parents of all patients will complete a proxy-report version of PSC-17. Disease outcome measures will include: Physician/Patient/Parent Global Assessments of Disease Activity, Disease Activity Score, Manual Muscle Testing-8, Childhood Myositis Assessment Scale, Cutaneous Dermatomyositis Disease Area and Severity Index, Extramuscular Disease Global Assessment, Patient-Reported Outcomes Measurement Information System (PROMIS) Mobility and Upper Extremity Function, and muscle enzymes. Self-report and parent-proxy data on healthy behaviors, including medication adherence (Domains of Subjective Extent of Nonadherence), PROMIS Physical Activity, and photoprotection (Measures of Sun Exposure and Sun Protection Practices for Behavioral and Epidemiological Research) will be collected. Rates of completion of PSC-17/PHQ-9/GAD-7 and missingness of data will be calculated to assess feasibility. Acceptability of these measures will be assessed by 5-point Likert scale. Comparison of disease outcomes and healthy behaviors in screen positive vs negative patients will be conducted using two-sample t-tests. A follow-up survey will be sent to parents of screen positive patients 1 month after the visit to assess barriers to obtaining mental health care for their child.

Results: This study will operationalize and establish: 1) feasibility of mental health screening in JM (data completeness using 3 validated measures); 2) relationship of mental health symptoms with disease severity and physical function; 3) potential mechanisms for differential health outcomes in JM patients with mental health comorbidities (i.e. differences in medication adherence, physical activity, and photoprotection).

Conclusion: This study represents the first attempt to demonstrate feasibility of routine mental health screening in JM. Pilot data will be used to inform the design and conduct of larger multicenter studies of mental health in JM across the CARRA network. Findings could potentially be generalized to other pediatric rheumatology practices and patient populations.


Disclosure: K. Ardalan, None; A. Manning, None; B. Feldman, OPTUM, Pfizer, AB2-Bio, 1; G. Maslow, None; A. Knight, None.

To cite this abstract in AMA style:

Ardalan K, Manning A, Feldman B, Maslow G, Knight A. Feasibility and Pilot Study of Mental Health Screening in Juvenile Myositis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/feasibility-and-pilot-study-of-mental-health-screening-in-juvenile-myositis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/feasibility-and-pilot-study-of-mental-health-screening-in-juvenile-myositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology